IntelGenx Announces Issuance of Second U.S. Patent for Topical Oral Film Technology
May 01 2019 - 8:00AM
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading
oral drug delivery company, today announced that the United States
Patent and Trademark Office has issued U.S. Patent 10,272,038
entitled “Film Dosage Form with Extended Release Mucoadhesive
Particles.” The patent covers the design and manufacturing of
topical oral films (“TOF”) for the local (topical) treatment of
diseases of the oral mucosa using mucoadhesive particles.
This patent is in the same family as U.S. Patent
9,668,970 – issued to IntelGenx in June 2017 – and provides broader
coverage for IntelGenx’s proprietary technology, which is intended
to provide sustained release of an active agent to a target area of
the oral cavity. The technology is useful for the topical treatment
of oral diseases and conditions such as gingivitis, buccal ulcers,
canker sores, Sjögren’s syndrome, oral mucositis and Behcet’s
disease.
“This is the second orange book eligible U.S
patent IntelGenx has been granted for our topical oral film
technology, and it reflects our strategy to broaden and diversify
our intellectual property portfolio to obtain protection for the
many applications of our VersaFilm® technology,” said Horst G.
Zerbe, CEO of IntelGenx. “In this case, we believe our technology
offers a novel and potentially superior treatment option for oral
diseases such as Sjögren’s syndrome and oral mucositis, both of
which represent significant unmet medical need and a large market
opportunity.”
The market opportunity for treatments of oral
disease and conditions is large and growing. For example, available
data indicate that the global market for oral mucositis treatments
is approximately USD$2 billion, and is expected to grow at a
compound annual rate of approximately 7% through to 2024, while the
global Sjögren’s syndrome market is expected to reach USD$2 billion
by 2024.
About IntelGenx Topical Oral
Film
IntelGenx’s TOF has a unique mode of action. It
facilitates the controlled release of an active agent to the buccal
cavity and its transport through the oral mucosa, while avoiding
the discomfort often associated with conventional long lasting
mucoadhesive films or tablets. The controlled release of an active
agent for local action in the buccal cavity is achieved by
providing an oral film in which small sized mucoadhesive particles
containing the active agent are dispersed in a disintegrating film
matrix. Upon administration in the oral cavity, the film quickly
disintegrates and releases the mucoadhesive particles which will
bind to the oral mucosa. The active agent can be released from the
mucoadhesive particles over a prolonged period of time as the
mucoadhesive material slowly dissolves or erodes.
About IntelGenx
Established in 2003, IntelGenx is a leading oral
drug delivery company primarily focused on the development and
manufacturing of innovative pharmaceutical oral films based on its
proprietary VersaFilm® and VetaFilm™ technology platforms.
IntelGenx's highly skilled team provides
comprehensive pharmaceuticals services to pharmaceutical partners,
including R&D, analytical method development, clinical
monitoring, IP and regulatory services. IntelGenx's
state-of-the-art manufacturing facility, which was established for
oral film technology platforms, offers by supporting lab-scale to
pilot- and commercial-scale production. More information about the
company can be found at www.intelgenx.com.
Forward Looking Statements
This document may contain forward-looking
information about IntelGenx's operating results and business
prospects that involve substantial risks and uncertainties.
Statements that are not purely historical are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and Section 27A of the Securities
Act of 1933, as amended. These statements include, but are not
limited to, statements about IntelGenx's plans, objectives,
expectations, strategies, intentions or other characterizations of
future events or circumstances and are generally identified by the
words "may," "expects," "anticipates," "intends," "plans,"
"believes," "seeks," "estimates," "could," "would," and similar
expressions. All forward looking statements are expressly qualified
in their entirety by this cautionary statement. Because these
forward-looking statements are subject to a number of risks and
uncertainties, IntelGenx's actual results could differ materially
from those expressed or implied by these forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, those discussed under
the heading "Risk Factors" in IntelGenx's annual report on Form
10-K, filed with the United States Securities and Exchange
Commission and available at www.sec.gov, and also filed with
Canadian securities regulatory authorities at www.sedar.com.
IntelGenx assumes no obligation to update any such forward-looking
statements.
Each of the TSX Venture Exchange and OTCQX has
neither approved nor disapproved the contents of this press
release. Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Source: IntelGenx Technologies
Corp.
For IntelGenx
Stephen Kilmer
Investor Relations
(514) 331-7440 ext 232
stephen@intelgenx.com
Or
Andre Godin, CPA, CA
Executive Vice-President and CFO
IntelGenx Corp.
(514) 331-7440 ext 203
andre@intelgenx.com
Intelgenx Technologies (TSXV:IGX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Intelgenx Technologies (TSXV:IGX)
Historical Stock Chart
From Sep 2023 to Sep 2024